Avenue Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Avenue Therapeutics's estimated annual revenue is currently $1.9M per year.
- Avenue Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Avenue Therapeutics has 12 Employees.
- Avenue Therapeutics grew their employee count by -8% last year.
Avenue Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO and Member Board Directors | Reveal Email/Phone |
2 | Chief Financial Officer | Reveal Email/Phone |
3 | VP Clinical Operations and Program Management | Reveal Email/Phone |
Avenue Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.6M | 4 | 0% | N/A | N/A |
#2 | $3.7M | 24 | 41% | $44M | N/A |
#3 | $6.2M | 40 | -7% | N/A | N/A |
#4 | $42M | 271 | -1% | N/A | N/A |
#5 | $12.7M | 82 | 0% | $10M | N/A |
#6 | $2.5M | 16 | 0% | N/A | N/A |
#7 | $7.5M | 45 | 0% | $51.6M | N/A |
#8 | $0.2M | 1 | -50% | N/A | N/A |
#9 | $4.3M | 26 | -16% | $3.3M | N/A |
#10 | $3.7M | 24 | 4% | N/A | N/A |
What Is Avenue Therapeutics?
Avenue Therapeutics, Inc. (NASDAQ: ATXI), a Fortress Biotech (NASDAQ: FBIO) Company, is a specialty pharmaceutical company focused on the development and commercialization of intravenous (IV) tramadol for the management of moderate to moderately severe postoperative pain. IV tramadol may fill a gap in the acute pain market between IV acetaminophen/NSAIDS and IV conventional narcotics. Avenue is currently evaluating IV tramadol in a pivotal Phase 3 program for the management of postoperative pain.
keywords:N/A
N/A
Total Funding
12
Number of Employees
$1.9M
Revenue (est)
-8%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in New York
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1M | 12 | -84% | N/A |
#2 | $0.6M | 12 | 0% | $5.2M |
#3 | $1.2M | 12 | 20% | N/A |
#4 | $1M | 12 | N/A | N/A |
#5 | $1M | 12 | N/A | N/A |